Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Bykomcyin

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Framycetin (sulfate), Fradiomycin b (sulfate); neomycin b (sulfate), Neomycin sulfate, 4146-30-9, Bcp28374, Neomycin sulfate; neomycin sulphate b
    Molecular Formula
    C23H52N6O25S3
    Molecular Weight
    908.9  g/mol
    InChI Key
    KWBUARAINLGYMG-UHFFFAOYSA-N
    Aminoglycoside antibiotic complex produced by Streptomyces fradiae. It is composed of neomycins A, B, and C, and acts by inhibiting translation during protein synthesis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-amino-2-(aminomethyl)-6-[4,6-diamino-2-[4-[3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid
    2.1.2 InChI
    InChI=1S/C23H46N6O13.3H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;3*1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;3*(H2,1,2,3,4)
    2.1.3 InChI Key
    KWBUARAINLGYMG-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Fradiomycin Sulfate

    2. Neomycin

    3. Neomycin Palmitate

    4. Neomycin Sulfate

    2.2.2 Depositor-Supplied Synonyms

    1. Framycetin (sulfate)

    2. Fradiomycin B (sulfate); Neomycin B (sulfate)

    3. Neomycin Sulfate

    4. 4146-30-9

    5. Bcp28374

    6. Neomycin Sulfate; Neomycin Sulphate B

    2.3 Create Date
    2009-08-08
    3 Chemical and Physical Properties
    Molecular Weight 908.9 g/mol
    Molecular Formula C23H52N6O25S3
    Hydrogen Bond Donor Count19
    Hydrogen Bond Acceptor Count31
    Rotatable Bond Count9
    Exact Mass908.21442469 g/mol
    Monoisotopic Mass908.21442469 g/mol
    Topological Polar Surface Area602 Ų
    Heavy Atom Count57
    Formal Charge0
    Complexity953
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count19
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count4
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 20  
    Drug NameNEO-SYNALAR
    Active IngredientFLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
    CompanyMEDIMETRIKS PHARMS (Application Number: A060700)

    2 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATE
    Active IngredientNEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyWATSON LABS (Application Number: A062664); X GEN PHARMS (Application Number: A065106); X GEN PHARMS (Application Number: A065108)

    3 of 20  
    Drug NameNEOSPORIN G.U. IRRIGANT
    Active IngredientNEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyMONARCH PHARMS (Application Number: A060707)

    4 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
    Active IngredientBACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyAKORN (Application Number: A065088); BAUSCH AND LOMB (Application Number: A064064); PERRIGO CO TENNESSEE (Application Number: A060764)

    5 of 20  
    Drug NameNEOSPORIN
    Active IngredientBACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyCASPER PHARMA LLC (Application Number: N050417)

    6 of 20  
    Drug NameDEXASPORIN
    Active IngredientDEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyBAUSCH AND LOMB (Application Number: A064135)

    7 of 20  
    Drug NameMAXITROL
    Active IngredientDEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyNOVARTIS PHARMS CORP (Application Number: N050023); NOVARTIS PHARMS CORP (Application Number: N050065); SANDOZ INC (Application Number: A062341)

    8 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
    Active IngredientDEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyBAUSCH AND LOMB (Application Number: A064063); PERRIGO CO TENNESSEE (Application Number: A062938)

    9 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
    Active IngredientGRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyAMRING PHARMS (Application Number: A065187); BAUSCH AND LOMB (Application Number: A064047)

    10 of 20  
    Drug NameNEOSPORIN
    Active IngredientGRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyMONARCH PHARMS (Application Number: A060582)

    11 of 20  
    Drug NameCORTISPORIN
    Active IngredientHYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyMONARCH PHARMS (Application Number: N050218)

    12 of 20  
    Drug NameCASPORYN HC
    Active IngredientHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyCASPER PHARMA LLC (Application Number: N060613)

    13 of 20  
    Drug NameCORTISPORIN
    Active IngredientHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyMONARCH PHARMS (Application Number: N050479)

    14 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
    Active IngredientHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyAMRING PHARMS (Application Number: A065216); AMRING PHARMS (Application Number: A065219); BAUSCH AND LOMB (Application Number: A064053); SANDOZ INC (Application Number: A062423); SANDOZ INC (Application Number: A062488); SANDOZ INC (Application Number: A062874)

    15 of 20  
    Drug NameOTICAIR
    Active IngredientHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyBAUSCH AND LOMB (Application Number: A064065)

    16 of 20  
    Drug NameBACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE
    Active IngredientBACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyPERRIGO CO TENNESSEE (Application Number: A062166)

    17 of 20  
    Drug NameCORTISPORIN
    Active IngredientBACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyMONARCH PHARMS (Application Number: N050168)

    18 of 20  
    Drug NameNEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE
    Active IngredientBACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
    CompanyAKORN (Application Number: A065213); BAUSCH AND LOMB (Application Number: A064068)

    19 of 20  
    Drug NameCOLY-MYCIN S
    Active IngredientCOLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
    CompanyENDO PHARMS INC (Application Number: N050356)

    20 of 20  
    Drug NameNEOMYCIN SULFATE
    Active IngredientNEOMYCIN SULFATE
    CompanyBRECKENRIDGE PHARM (Application Number: A065468); LANNETT CO INC (Application Number: A204435); TEVA (Application Number: A060304); X GEN PHARMS (Application Number: A065220)

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-Bacterial Agents

    Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

    Protein Synthesis Inhibitors

    Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)